Status
Conditions
Treatments
About
To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Traditional indications for vena cava filter in patients with established DVT or PE, including (40):
Patients with proven Pulmonary Embolus (PE) or Deep Vein Thrombosis (DVT) and one or more of the following:
Contraindication to anticoagulation
Complication of anticoagulation
Failure of anticoagulation
Poor compliance with anticoagulation medications
Extended indications for vena cava filter placement in patients with established DVT or PE, including the following (31, 40):
High risk trauma or orthopedic patients who cannot receive anticoagulation because of increased bleeding risk, and have one or more of the following injury patterns (31, 40):
Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
117 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal